Attached files

file filename
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex-31_1.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex-32_1.htm
EXCEL - IDEA: XBRL DOCUMENT - NeuBase Therapeutics, Inc.Financial_Report.xls
10-Q - QUARTERLY REPORT - NeuBase Therapeutics, Inc.ohrp-10q_033112.htm
EX-31.2 - CERTIFICATION OF INTERIM CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex-31_2.htm

 

Ohr Pharmaceutical, Inc. 10-Q

 

 

Exhibit 32.2

 

 

Certification of Chief Financial Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

 

Not Filed Pursuant to the Securities Exchange Act of 1934

 

In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof  (the “Report”), I, Sam Backenroth , Chief Financial Officer, of the Company , certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: May 11, 2012

 

/s/ Sam Backenroth  
Name:  Sam Backenroth  
Title:  Interim Chief Financial Officer